Company: INTS
Filing Date: 2025-10-31
Form Type: 8-K
Source: 0001628280-25-047855
Chunk: 0

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-10-31
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive Agreement

On October 30, 2025, Intensity Therapeutics, Inc., a Delaware corporation (the “ Company”), entered into a Securities Purchase Agreement (the “ Purchase Agreement”) with an institutional investor (the “ Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the “ Offering”), 5,000,000 shares (the “ Shares”) of common stock, par value $0.0001 per share, of the Company (“ Common Stock”) to the Investor, at a price of $0.80 per share, for aggregate gross proceeds to the Company of $4.0 million before deducting the placement agent’s fees and related offering expenses.

The Shares were offered by the Company pursuant to a Registration Statement on Form S-3 (File No. 333-280681), which was filed with the Securities and Exchange Commission (the “ Commission”) on July 3, 2024 and was declared effective by the Commission on July 11, 2024 (the “ Registration Statement”).

The Purchase Agreement contains customary representations and warranties, agreements of the Company and the Investor and customary indemnification rights and obligations of the parties. Pursuant to the terms of the Purchase Agreement, the Company has agreed to certain restrictions on the issuance and sale of its Common Stock or Common Stock Equivalents (as defined in the Purchase Agreement) during the 30-day period following the closing of the Offering.

The Offering is expected to close on or about November 3, 2025, subject to satisfaction of customary closing conditions.

On October 30, 2025, the Company entered into a placement agency agreement (the “ Placement Agent Agreement”) with A. G. P./Alliance Global Partners (“ A. G. P.”) pursuant to which the Company engaged A. G. P. as the placement agent (the “ Placement Agent”) in connection with the Offering. The Company agreed to pay the Placement Agent a fee in cash equal to 7.0% of the gross proceeds from the sale of the Shares to the Investor. The Company also agreed to reimburse the Placement Agent for all reasonable and documented out-of-pocket expenses, including the reasonable fees of legal counsel not to exceed $50,000. The Placement Agent Agreement also contains representations, warranties, indemnification and other provisions customary for transactions of this nature.

The foregoing summaries of the Placement Agent Agreement and the Purchase Agreement do not